8 completed. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 5 | Completed 5 |
Follow filanesib: new trials by email Literature Review of filanesib trials Research Report on filanesib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients Filanesib, pomalidomide and dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | PETHEMA Foundation | 47 | 2015-09-01 | 2022-07-27 |
| A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) Filanesib, KSP (Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous - Advanced Multiple Myeloma | Phase 2 | Completed | Pfizer | 154 | 2014-05-01 | 2020-10-19 |
| A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma Carfilzomib, proteasome inhibitor; intravenous, Filanesib, KSP(Eg5) inhibitor; intravenous, Dexamethasone, steroid; oral or intravenous - Advanced Multiple Myeloma | Phase 2 | Completed | Pfizer | 77 | 2013-11-01 | 2020-09-16 |
| Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Carfilzomib, Filanesib, Laboratory Biomarker Analysis - Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma | Phase 1 | Completed | M.D. Anderson Cancer Center | 76 | 2012-02-24 | 2019-07-16 |
| A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma ARRY-520, KSP(Eg5) inhibitor; intravenous, Bortezomib, proteasome inhibitor; intravenous or subcutaneous, Dexamethasone, steroid; oral - Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 55 | 2010-12-01 | 2020-09-30 |
| A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous, Dexamethasone, steroid; oral - Multiple Myeloma, Plasma Cell Leukemia | Phase 1 / Phase 2 | Completed | Pfizer | 55 | 2009-01-01 | 2020-10-19 |
| A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia ARRY-520, KSP(Eg5) inhibitor; intravenous - Advanced MDS, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Pfizer | 36 | 2008-03-18 | 2021-02-08 |
| A Study of ARRY-520 in Patients With Advanced Cancer ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous - Advanced Solid Tumors | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 41 | 2007-04-01 | 2020-09-28 |
Multiple Myeloma (4) · Leukemia, Plasma Cell (3) · Paraproteinemias (2) · Plasmacytoma (2) · Leukemia, Myeloid, Acute (1) · Preleukemia (1)
Pfizer (4) · Array Biopharma, now a wholly owned subsidiary of Pfizer (2) · M.D. Anderson Cancer Center (1) · PETHEMA Foundation (1)
United States (7) · Spain (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · United Kingdom (1)
Ocio Enrique, DR (1) · Robert Orlowski (1)
PMID 10564685, PMID 15902208, PMID 15958804, PMID 17975015, PMID 18032762, PMID 18032763, PMID 19901123, PMID 22139909, PMID 28817190, PMID 32501528, PMID 8797771
2014 (1), P30CA016672 (1)